Marksans Pharma Limited announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for two key formulations — Clonidine 100 microgram Tablets and Clonidine Hydrochloride 25 microgram Tablets.
In an exchange filing, the company stated that this authorization will allow Relonchem to market the approved products in the United Kingdom, expanding Marksans Pharma’s presence in the cardiovascular and central nervous system therapeutic segments.
Marksans Pharma, headquartered in Mumbai, operates across India, the USA, and the UK, with facilities approved by leading global regulatory agencies including USFDA, UK MHRA, and Australian TGA. The company’s diversified portfolio spans multiple therapeutic categories such as CVS, CNS, anti-diabetic, gastroenterological, and pain management products.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
